Market Introduction
Typhoid is an infectious disease caused by Salmonella Typhi, through ingestion of contaminated food and water. This intense illness is identified by prolonged fever, headache and nausea, loss of appetite and constipation or sometimes diarrhea. Increasing threats of typhoid and growing threats of drug resistance has helped typhoid vaccines to boost its market especially among rural and hard-to-reach communities where progress in medical services, infrastructure and development may be slow.
Market Overview and Dynamics
The Middle East and Africa typhoid fever vaccines market is expected to reach US$ US$ 37.09 million in 2027 from US$ 20.00 million in 2019. The market is estimated to grow with a CAGR of 8.3% from 2020-2027. Factors such as growing initiatives for typhoid fever in Middle East and Africa region and the key factor contributing to the growth of the market. On the other hand, the market is likely to have negative impact due to risk of associated with typhoid fever vaccines.
Key Market Segments
On the basis of vaccine type, the typhoid fever vaccines market has been segmented into live attenuated vaccine, capsular polysaccharide vaccines, conjugate vaccine, and others. The capsular polysaccharide vaccines segment held the largest share of the market in 2019, whereas the live attenuated vaccine segment is anticipated to register the highest CAGR in the market during the forecast period. Global typhoid fever vaccines market based on route of administration is segmented into oral and injectable. The injectable segment held the largest share of the market in 2019, whereas the oral segment is anticipated to register the highest CAGR in the market during the forecast period
Major Sources and Companies Listed
Some of the major secondary sources for Middle East and Africa typhoid fever vaccines market included in the report are, Severe Typhoid Fever in Africa (SETA), Gavi - the Vaccine Alliance, International Trade Administration, World Health Organization and others.
Reasons to buy the report
- To understand the Middle East and Africa typhoid fever vaccines market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Middle East and Africa typhoid fever vaccines market
- Efficiently plan M&A and partnership deals in Middle East and Africa typhoid fever vaccines market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Middle East and Africa typhoid fever vaccines market
- Obtain market revenue forecast for market by various segments from 2019-2027 in Middle East and Africa.
Middle East and Africa Typhoid Fever Vaccines Market
By Vaccine Type
- Live Attenuated Vaccine
- Capsular Polysaccharide Vaccines
- Conjugate Vaccine
- Others
By Route of Administration
- Oral
- Injectable
By Country
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Company Profiles
- GlaxoSmithKline plc
- Shanghai institute of biological products co. ltd.
- Sanofi
- Pax Vax Inc
- BHARAT BIOTECH